tirzepatide eli lilly direct Lilly, Maker of Mounjaro and Zepbound, Wades Into Telehealth Lilly releases Zepbound® (tirzepatide) single-dose

Its worth noting, however, that these cards have limits

O.HorvathT

Zepbound Data as Reported by Lilly The manufacturers language on the weight loss indication reads thus: Zepbound is indicated in combination with a reduced-calorie diet and increased physical activity: to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition. At 72 weeks, patients taking Zepbound 15mg lost an average of 20.9% of their body weight

The first four weeks are often a period of adjustment and early progress

PMC12151102

Side effects may include nausea, vomiting, diarrhea, constipation, abdominal pain, decreased appetite, and indigestion